This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 1378 |
severe acute | 691 |
respiratory syndrome | 655 |
respiratory distress | 613 |
liver failure | 600 |
intensive care | 599 |
lung injury | 560 |
distress syndrome | 550 |
mechanical ventilation | 472 |
acute lung | 414 |
acute bronchitis | 404 |
respiratory failure | 402 |
en el | 357 |
critically ill | 356 |
sickle cell | 298 |
pacientes con | 298 |
respiratory tract | 293 |
care unit | 292 |
septic shock | 261 |
acute liver | 259 |
risk factors | 247 |
en pacientes | 238 |
renal failure | 226 |
se recomienda | 222 |
ill patients | 215 |
pulmonary embolism | 214 |
los pacientes | 212 |
otitis media | 210 |
acute exacerbation | 202 |
pulmonary disease | 201 |
coronavirus disease | 200 |
pulmonary fibrosis | 199 |
chronic obstructive | 196 |
lung transplantation | 191 |
chronic bronchitis | 186 |
heart failure | 185 |
con covid | 185 |
mg kg | 184 |
novel coronavirus | 184 |
van het | 178 |
united states | 178 |
obstructive pulmonary | 176 |
syndrome coronavirus | 174 |
acute pancreatitis | 174 |
acute exacerbations | 173 |
idiopathic pulmonary | 162 |
liver transplantation | 161 |
liver disease | 160 |
organ failure | 157 |
may also | 157 |
sars coronavirus | 153 |
systematic review | 151 |
mortality rate | 144 |
controlled trial | 143 |
acute rejection | 143 |
see chapter | 143 |
acute kidney | 141 |
kidney injury | 141 |
upper respiratory | 141 |
en los | 137 |
virus infection | 134 |
stem cells | 132 |
lung disease | 131 |
chronic liver | 131 |
critical care | 130 |
sore throat | 125 |
nervous system | 125 |
case report | 122 |
el uso | 121 |
nitric oxide | 120 |
blood pressure | 120 |
clinical features | 119 |
kawasaki disease | 119 |
tract infections | 119 |
pulmonary artery | 118 |
cell disease | 117 |
doc id | 116 |
cord uid | 116 |
clinical trials | 116 |
streptococcal pharyngitis | 115 |
clinical course | 113 |
pulmonary edema | 113 |
del paciente | 113 |
myocardial infarction | 112 |
acute renal | 111 |
clinical characteristics | 111 |
viral infection | 111 |
pao fio | 110 |
heart disease | 110 |
bone marrow | 110 |
hepatic failure | 109 |
control group | 109 |
patients admitted | 107 |
transplant recipients | 107 |
antibiotic treatment | 107 |
may occur | 106 |
mesenchymal stem | 105 |
ards patients | 103 |
adult patients | 102 |
cell anaemia | 102 |
cohort study | 102 |
antibiotic therapy | 101 |
hepatic encephalopathy | 101 |
cardiac output | 100 |
two groups | 100 |
hong kong | 98 |
icu patients | 98 |
left ventricular | 97 |
para el | 97 |
interstitial pneumonia | 95 |
severe hepatitis | 95 |
acute pulmonary | 95 |
el paciente | 95 |
por covid | 94 |
viral infections | 94 |
immune response | 94 |
prospective study | 93 |
tidal volume | 93 |
lower respiratory | 93 |
blood flow | 93 |
significantly higher | 93 |
liver function | 93 |
world health | 92 |
con el | 92 |
cardiac arrest | 91 |
clinical trial | 91 |
hospitalized patients | 89 |
chronic hepatitis | 89 |
inflammatory response | 89 |
histologic study | 89 |
infectious diseases | 88 |
ali ards | 88 |
public health | 88 |
central nervous | 88 |
hospital mortality | 86 |
disseminated encephalomyelitis | 86 |
acute disseminated | 86 |
lung transplant | 84 |
right ventricular | 84 |
mean age | 83 |
health organization | 83 |
multiple organ | 83 |
mechanically ventilated | 82 |
respiratory infections | 82 |
antibiotic use | 82 |
diffuse alveolar | 81 |
associated conditions | 80 |
ml kg | 80 |
acute otitis | 80 |
statistically significant | 79 |
spike protein | 79 |
con un | 79 |
retrospective study | 79 |
alveolar damage | 79 |
possible associated | 78 |
study group | 78 |
health care | 78 |
sars patients | 78 |
randomized controlled | 77 |
severe ards | 77 |
clinical practice | 77 |
side effects | 77 |
con sospecha | 76 |
gas exchange | 75 |
common cold | 75 |
converting enzyme | 75 |
care units | 75 |
coronary artery | 74 |
endothelial cells | 74 |
antimicrobial therapy | 74 |
severe cases | 73 |
differential diagnosis | 73 |
apache ii | 73 |
pulmonary hypertension | 73 |
spinal cord | 73 |
primary care | 73 |
bacterial infection | 73 |
heart rate | 72 |
severe covid | 72 |
see also | 72 |
specimen preparation | 72 |
controlled trials | 72 |
sin embargo | 71 |
epithelial cells | 71 |
increased risk | 71 |
icu admission | 71 |
paciente con | 71 |
emergency department | 71 |
patients treated | 71 |
membrane oxygenation | 70 |
fulminant hepatic | 70 |
extracorporeal membrane | 70 |
may lead | 70 |
cardiac surgery | 70 |
arterial blood | 70 |
computed tomography | 69 |
expected findings | 68 |
con una | 68 |
acute pe | 68 |
acute sinusitis | 67 |
tract infection | 67 |
acute cough | 65 |
related terms | 65 |
arterial pressure | 65 |
airway pressure | 65 |
poor prognosis | 64 |
acute phase | 64 |
influenza virus | 64 |
cardiogenic shock | 64 |
patients without | 64 |
hbv infection | 64 |
viral hepatitis | 63 |
clinical manifestations | 63 |
lupus erythematosus | 63 |
viral replication | 62 |
en un | 62 |
growth factor | 62 |
adverse effects | 62 |
stem cell | 62 |
risk factor | 62 |
prone position | 62 |
case series | 61 |
patients receiving | 61 |
within hours | 61 |
may cause | 61 |
sars cov | 60 |
endomyocardial biopsy | 60 |
type ii | 60 |
pulmonary function | 60 |
significant differences | 60 |
external examination | 60 |
viral load | 60 |
abdominal pain | 59 |
coronavirus infection | 59 |
ventilated patients | 59 |
human coronavirus | 59 |
acute myocarditis | 59 |
renal disease | 59 |
fi brosis | 58 |
streptococcus pneumoniae | 58 |
lung function | 58 |
acute hepatitis | 58 |
clinical presentation | 58 |
acquired pneumonia | 57 |
among patients | 57 |
submit samples | 57 |
invasive ventilation | 57 |
mg dl | 57 |
rheumatic fever | 57 |
patients may | 57 |
ml min | 57 |
adult respiratory | 56 |
mm hg | 56 |
respiratory syncytial | 56 |
liver injury | 56 |
renal function | 56 |
icu stay | 56 |
chain reaction | 55 |
pulmonary fi | 55 |
pg ml | 55 |
el manejo | 55 |
pulmonary vascular | 55 |
type i | 55 |
acute chest | 55 |
high mortality | 55 |
polymerase chain | 54 |
severe sepsis | 54 |
se debe | 54 |
respiratory symptoms | 53 |
common cause | 53 |
syncytial virus | 53 |
por sars | 53 |
chest radiograph | 52 |
multiple sclerosis | 52 |
pacientes en | 52 |
group i | 52 |
scoring system | 52 |
bronchoalveolar lavage | 52 |
mortality rates | 52 |
chest syndrome | 52 |
el riesgo | 52 |
logistic regression | 52 |
dilated cardiomyopathy | 52 |
se ha | 51 |
peripheral blood | 51 |
early diagnosis | 51 |
magnetic resonance | 51 |
uncomplicated acute | 51 |
liver cells | 51 |
un estudio | 51 |
giant cell | 51 |
central venous | 51 |
por el | 50 |
respiratory rate | 50 |
significant difference | 50 |
significantly lower | 50 |
acute pharyngitis | 50 |
organ dysfunction | 50 |
intracranial hypertension | 50 |
animal models | 50 |
two patients | 50 |
factors associated | 50 |
hand column | 49 |
associated coronavirus | 49 |
pressure support | 49 |
reactive protein | 49 |
observational study | 49 |
ventilatory support | 49 |
study period | 49 |
immune system | 49 |
acute gastroenteritis | 49 |
ng ml | 49 |
lung biopsy | 49 |
commonly used | 48 |
barr virus | 48 |
oxygen saturation | 48 |
chest pain | 48 |
high risk | 48 |
van een | 48 |
patients presenting | 48 |
electron microscopy | 48 |
lopinavir ritonavir | 48 |
acute samples | 47 |
noninvasive ventilation | 47 |
important role | 47 |
first days | 47 |
sputum production | 47 |
predictive value | 47 |
acute myocardial | 47 |
immunodeficiency virus | 47 |
respiratory viruses | 47 |
patients undergoing | 47 |
neonatal lupus | 47 |
may result | 46 |
infected patients | 46 |
diabetes mellitus | 46 |
pressure ventilation | 46 |
se puede | 46 |
clinical outcomes | 46 |
intracranial pressure | 46 |
critical illness | 46 |
one study | 46 |
respiratory infection | 46 |
blood cells | 46 |
body weight | 46 |
case reports | 46 |
cardiac index | 46 |
related acute | 46 |
red blood | 45 |
cuidados intensivos | 45 |
brain injury | 45 |
clinical outcome | 45 |
within days | 45 |
human immunodeficiency | 45 |
blood gas | 45 |
blood transfusion | 45 |
transverse myelitis | 45 |
tidal volumes | 45 |
inflammatory cytokines | 44 |
disease severity | 44 |
oxygen therapy | 44 |
procedures depend | 44 |
one patient | 44 |
induced lung | 44 |
nephrotic syndrome | 44 |
induced acute | 44 |
ct scan | 44 |
replacement therapy | 44 |
middle east | 44 |
vascular resistance | 44 |
en las | 44 |
submit sample | 44 |
higher mortality | 44 |
several studies | 43 |
care medicine | 43 |
toxic shock | 43 |
septal defect | 43 |
el grupo | 43 |
cytokine storm | 43 |
copd exacerbations | 43 |
haemophilus influenzae | 43 |
acute care | 43 |
multivariate analysis | 43 |
copd patients | 43 |
patients received | 42 |
brain edema | 42 |
marrow transplantation | 42 |
treatment failure | 42 |
heart block | 42 |
sudden death | 42 |
el tratamiento | 42 |
east respiratory | 42 |
retrospective cohort | 42 |
congenital heart | 42 |
cov infection | 42 |
herpes simplex | 42 |
may develop | 42 |
grossly identified | 41 |
necrosis factor | 41 |
kg min | 41 |
interstitial lung | 41 |
survival rate | 41 |
high levels | 41 |
sclerosi multipla | 41 |
recent studies | 41 |
clinical symptoms | 41 |
rheumatoid arthritis | 41 |
renal replacement | 41 |
ii score | 41 |
plasma levels | 40 |
congestive heart | 40 |
clinical picture | 40 |
ejection fraction | 40 |
identified abnormalities | 40 |
prognostic factors | 40 |
gene expression | 40 |
respiratory system | 40 |
higher risk | 40 |
adverse events | 40 |
bronchiolitis obliterans | 40 |
myocardial injury | 40 |
another study | 39 |
induced pulmonary | 39 |
organizing pneumonia | 39 |
plasma convaleciente | 39 |
first hours | 39 |
mean arterial | 39 |
associated pneumonia | 39 |
endothelial cell | 39 |
plasminogen activator | 39 |
prone positioning | 39 |
cerebrospinal fluid | 39 |
por lo | 39 |
inflammatory cells | 39 |
escherichia coli | 39 |
day mortality | 39 |
shock syndrome | 39 |
viral rna | 38 |
randomized trial | 38 |
significant increase | 38 |
clinical signs | 38 |
en una | 38 |
acute hemorrhagic | 38 |
natural history | 38 |
blood cell | 38 |
hyaline membranes | 38 |
young children | 38 |
supportive care | 38 |
years old | 38 |
least one | 38 |
physical examination | 38 |
cell count | 38 |
trauma patients | 38 |
bacterial infections | 38 |
blood gases | 38 |
en cuenta | 38 |
liver cell | 37 |
white blood | 37 |
acute bacterial | 37 |
renal involvement | 37 |
may present | 37 |
acute necrotizing | 37 |
cell myocarditis | 37 |
cell anemia | 37 |
pediatric patients | 37 |
intravenous immunoglobulin | 37 |
patients died | 37 |
connective tissue | 36 |
task force | 36 |
infectious disease | 36 |
brain stem | 36 |
among children | 36 |
liver diseases | 36 |
cell transplantation | 36 |
poor outcome | 36 |
liver cirrhosis | 36 |
positive pressure | 36 |
cancer patients | 36 |
randomised controlled | 36 |
viral myocarditis | 36 |
right heart | 36 |
lactate levels | 36 |
derived mesenchymal | 36 |
gastrointestinal tract | 36 |
systemic lupus | 35 |
statistical analysis | 35 |
air embolism | 35 |
data suggest | 35 |
even though | 35 |
myocardial damage | 35 |
head injury | 35 |
free days | 35 |
inflammatory mediators | 35 |
nasal cannula | 35 |
di emad | 35 |
fulminant hepatitis | 35 |
fio ratio | 35 |
elderly patients | 34 |
hospital stay | 34 |
middle ear | 34 |
hiv infection | 34 |
neurological manifestations | 34 |
right ventricle | 34 |
many patients | 34 |
present study | 34 |
clinical studies | 34 |
emergency room | 34 |
defi ciency | 34 |
pulmonary arterial | 34 |
intravascular coagulation | 34 |
diagnostic criteria | 34 |
congenital erythropoietic | 33 |
patients infected | 33 |
liver insufficiency | 33 |
erythropoietic porphyria | 33 |
gastrointestinal bleeding | 33 |
lung allograft | 33 |
carbon monoxide | 33 |
procedures described | 33 |
also known | 33 |
proinflammatory cytokines | 33 |
con los | 33 |
failure may | 33 |
acute infectious | 33 |
saps ii | 33 |
th day | 33 |
biopsy specimens | 33 |
infl ammatory | 33 |
convalescent plasma | 33 |
enteral nutrition | 33 |
mycoplasma pneumoniae | 33 |
erythema multiforme | 32 |
oxidative stress | 32 |
immunocompromised patients | 32 |
widely used | 32 |
two cases | 32 |
systemic inflammatory | 32 |
blood cultures | 32 |
new york | 32 |
cardiac function | 32 |
todos los | 32 |
high frequency | 32 |
life support | 32 |
consecutive patients | 32 |
recent years | 32 |
incubation period | 32 |
care workers | 32 |
antibiotic resistance | 32 |
cardiac involvement | 32 |
staphylococcus aureus | 32 |
determine whether | 32 |
tumor necrosis | 32 |
clinical findings | 32 |
venous thromboembolism | 32 |
syndrome associated | 31 |
septic patients | 31 |
may help | 31 |
respiratory illness | 31 |
common causes | 31 |
gevolg van | 31 |
randomized clinical | 31 |
liver biopsy | 31 |
gastrointestinal symptoms | 31 |
allograft rejection | 31 |
coronavirus pneumonia | 31 |
blood vessels | 31 |
per year | 31 |
type hepatitis | 31 |
lymph nodes | 31 |
higher incidence | 31 |
hepatorenal syndrome | 31 |
immune responses | 31 |
necrotizing encephalopathy | 31 |
nucleocapsid protein | 31 |
patients requiring | 31 |
hematopoietic stem | 31 |
acute onset | 31 |
kidney disease | 31 |
bacterial pathogens | 31 |
cerebral edema | 31 |
cardiovascular disease | 31 |
chlamydia pneumoniae | 30 |
gold standard | 30 |
acute coronary | 30 |
host disease | 30 |
medical history | 30 |
se han | 30 |
care physicians | 30 |
long term | 30 |
lung parenchyma | 30 |
informed consent | 30 |
ventricular function | 30 |
university hospital | 30 |
chronic sinusitis | 30 |
platelet count | 30 |
en uci | 30 |
spontaneous breathing | 30 |
patients hospitalized | 30 |
study showed | 30 |
human respiratory | 30 |
en su | 30 |
acute interstitial | 30 |
ventricular dysfunction | 30 |
blood samples | 30 |
antimicrobial agents | 30 |
retrospective analysis | 29 |
acute diarrhea | 29 |
acute viral | 29 |
clinical diagnosis | 29 |
portal hypertension | 29 |
toxicologic study | 29 |
flow nasal | 29 |
los estudios | 29 |
disseminated intravascular | 29 |
corticosteroid therapy | 29 |
white matter | 29 |
large number | 29 |
failure due | 29 |
amino acids | 29 |
severe liver | 29 |
function tests | 29 |
fungal infections | 29 |
early phase | 29 |
enteral feeding | 29 |
parenteral nutrition | 29 |
per day | 29 |
als gevolg | 29 |
vein thrombosis | 29 |
su uso | 29 |
elevated levels | 29 |
resonance imaging | 29 |
obliterative bronchiolitis | 28 |
pulmonary arteries | 28 |
chronic renal | 28 |
association studies | 28 |
con sdra | 28 |
het middenoor | 28 |
eosinophilic pneumonia | 28 |
del virus | 28 |
clinical significance | 28 |
appropriate antibiotic | 28 |
neutropenic patients | 28 |
within weeks | 28 |
acute rheumatic | 28 |
underlying disease | 28 |
laboratory tests | 28 |
group ii | 28 |
significant decrease | 28 |
fi ndings | 28 |
small airways | 28 |
debe ser | 28 |
endotracheal tube | 28 |
como el | 28 |
respiratory disease | 28 |
included patients | 28 |
pleural effusion | 28 |
high incidence | 28 |
carbon dioxide | 28 |
may play | 28 |
recent study | 28 |
vena cava | 28 |
coronavirus spike | 28 |
cell death | 27 |
bacterial gastroenteritis | 27 |
year period | 27 |
alveolar hemorrhage | 27 |
also may | 27 |
lactate dehydrogenase | 27 |
artery catheter | 27 |
es un | 27 |
berlin definition | 27 |
clinical improvement | 27 |
venous pressure | 27 |
blood product | 27 |
invasive mechanical | 27 |
stimulating factor | 27 |
infection may | 27 |
increased significantly | 27 |
severe disease | 27 |
patient population | 27 |
immunosuppressive therapy | 27 |
lung cancer | 27 |
tubular necrosis | 27 |
derived mscs | 27 |
purulent sputum | 27 |
skin lesions | 27 |
infection control | 27 |
respiratory pathogens | 27 |
ischemic stroke | 27 |
inhaled nitric | 27 |
american college | 27 |
high dose | 27 |
puede ser | 27 |
renal dysfunction | 27 |
kg day | 27 |
may show | 27 |
ontsteking van | 26 |
beide zijden | 26 |
response syndrome | 26 |
pulmonary infection | 26 |
blood loss | 26 |
year old | 26 |
pulmonary infiltrates | 26 |
urinary tract | 26 |
literature review | 26 |
age years | 26 |
requiring mechanical | 26 |
beneficial effect | 26 |
first week | 26 |
simplex virus | 26 |
increased mortality | 26 |
oxygen delivery | 26 |
randomized trials | 26 |
renal impairment | 26 |
severe respiratory | 26 |
hemolytic anemia | 26 |
one case | 26 |
el cual | 26 |
coronavirus associated | 26 |
chest radiographs | 26 |
serum creatinine | 26 |
surgical patients | 26 |
beneficial effects | 26 |
hemodynamic parameters | 26 |
chest radiography | 26 |
renal recovery | 26 |
disease progression | 26 |
dendritic cells | 25 |
blood alcohol | 25 |
european society | 25 |
positive end | 25 |
oxide synthase | 25 |
nosocomial infections | 25 |
pilot study | 25 |
young adults | 25 |
additional information | 25 |
leading cause | 25 |
virus infections | 25 |
lung rejection | 25 |
three patients | 25 |
brain death | 25 |
human coronaviruses | 25 |
paraquat poisoning | 25 |
working group | 25 |
practice guidelines | 25 |
patienten mit | 25 |
blood volume | 25 |
productive cough | 25 |
antiviral drugs | 25 |
airway obstruction | 25 |
evidence suggests | 25 |
hospital discharge | 25 |
el momento | 25 |
portal vein | 25 |
en este | 25 |
streptococcal infection | 25 |
prognostic value | 25 |
short term | 25 |
liver damage | 25 |
coronavirus oc | 25 |
del sistema | 25 |
effect size | 25 |
cuidado intensivo | 25 |
el inicio | 25 |
significantly reduced | 25 |
associated acute | 25 |
myocardial involvement | 25 |
umbilical cord | 25 |
see table | 25 |
blood lactate | 24 |
clinical criteria | 24 |
en contra | 24 |
heart surgery | 24 |
positive patients | 24 |
activated protein | 24 |
major cause | 24 |
pneumoniae infection | 24 |
coronavirus infections | 24 |
clinical response | 24 |
immune complexes | 24 |
acute eosinophilic | 24 |
also occur | 24 |
spotted fever | 24 |
expiratory pressure | 24 |
mononuclear cells | 24 |
five patients | 24 |
hyperacute rejection | 24 |
results suggest | 24 |
may benefit | 24 |
uremic syndrome | 24 |
strep throat | 24 |
throat culture | 24 |
exclusion criteria | 24 |
also found | 24 |
therapy may | 24 |
significantly different | 24 |
teniendo en | 24 |
bridging necrosis | 24 |
induced liver | 24 |
alveolar epithelial | 24 |
ventricular septal | 24 |
hypoxemic respiratory | 24 |
situ hybridization | 24 |
endotracheal intubation | 24 |
hepatic cirrhosis | 24 |
serum bilirubin | 24 |
nucleic acid | 24 |
independent risk | 24 |
cystic fibrosis | 24 |
sobre el | 24 |
postoperative period | 24 |
see prokoplab | 24 |
class i | 24 |
purpura fulminans | 24 |
en caso | 24 |
acquired immunodeficiency | 24 |
remains unclear | 24 |
el tiempo | 23 |
liver transplant | 23 |
north america | 23 |
less common | 23 |
methyl bromide | 23 |
also reported | 23 |
histologic features | 23 |
extubation failure | 23 |
disease may | 23 |
associated nephropathy | 23 |
red cell | 23 |
acute transverse | 23 |
lung allografts | 23 |
term outcome | 23 |
cardiovascular system | 23 |
infectious agents | 23 |
transplant patients | 23 |
overall mortality | 23 |
jugular bulb | 23 |
increased levels | 23 |
avian influenza | 23 |
oxygen consumption | 23 |
practice guideline | 23 |
disease control | 23 |
myocardial dysfunction | 23 |
vital signs | 23 |
ventricular arrhythmias | 23 |
general practice | 23 |
older age | 23 |
severe head | 23 |
gastric contents | 23 |
el personal | 23 |
renal tubular | 23 |
microbial load | 23 |
patients will | 23 |
tissue damage | 23 |
failure patients | 23 |
twice daily | 23 |
pulmonary oedema | 23 |
si el | 23 |
hemolytic uremic | 23 |
measured using | 23 |
icu mortality | 23 |
fatal cases | 23 |
significantly associated | 23 |
previously healthy | 23 |
obliterans syndrome | 23 |
vascular endothelial | 23 |
hemolytic streptococci | 22 |
lung pathology | 22 |
adhesion molecule | 22 |
viral particles | 22 |
fi rst | 22 |
sample size | 22 |
exchange transfusion | 22 |
mountain spotted | 22 |
chronic kidney | 22 |
previous studies | 22 |
left ventricle | 22 |
body temperature | 22 |
international society | 22 |
general population | 22 |
infectious diarrhea | 22 |
multicenter study | 22 |
solid organ | 22 |
treated patients | 22 |
affected patients | 22 |
high doses | 22 |
consensus conference | 22 |
una serie | 22 |
significantly increased | 22 |
kidney transplantation | 22 |
studied patients | 22 |
acute infection | 22 |
atlanta classification | 22 |
heart transplantation | 22 |
transbronchial biopsy | 22 |
medical care | 22 |
clinical study | 22 |
sofa score | 22 |
normal range | 22 |
controlled study | 22 |
antimicrobial resistance | 22 |
rocky mountain | 22 |
consentimiento informado | 22 |
glass opacities | 22 |
mean values | 22 |
performed using | 22 |
gas analysis | 22 |
immune cells | 22 |
bacterial pneumonia | 22 |
liver dysfunction | 22 |
disease onset | 22 |
sickle hb | 22 |
es una | 22 |
patients required | 22 |
noninvasive positive | 22 |
immunodeficiency syndrome | 22 |
del estado | 22 |
lung tissue | 22 |
nasal discharge | 22 |
may contribute | 22 |
ill adults | 22 |
coronary arteries | 22 |
age groups | 22 |
pulmonary angiography | 22 |
organ transplantation | 22 |
early stage | 22 |
artery pressure | 21 |
follow procedures | 21 |
oleic acid | 21 |
clinical management | 21 |
cell damage | 21 |
falla respiratoria | 21 |
protective effect | 21 |
control study | 21 |
age group | 21 |
care patients | 21 |
fl uid | 21 |
hospital admissions | 21 |
infected pneumonia | 21 |
high fever | 21 |
reactive oxygen | 21 |
para pacientes | 21 |
massive necrosis | 21 |
may reveal | 21 |
acute glomerulonephritis | 21 |
molecular weight | 21 |
respiratory support | 21 |
los casos | 21 |
disease process | 21 |
hepatocellular carcinoma | 21 |
liver support | 21 |
pregnant women | 21 |
para los | 21 |
bile duct | 21 |
aan beide | 21 |
atrial fibrillation | 21 |
days later | 21 |
hla antibodies | 21 |
lung diseases | 21 |
inotropic support | 21 |
systemic inflammation | 21 |
odds ratio | 21 |
first day | 21 |
cardiogenic pulmonary | 21 |
laboratory findings | 21 |
upper airway | 21 |
early stages | 21 |
cardiac dysfunction | 21 |
wide range | 21 |
children aged | 21 |
adhesion molecules | 21 |
het trommelvlies | 21 |
reported cases | 21 |
blood products | 21 |
three cases | 21 |
time course | 20 |
fatty acids | 20 |
also present | 20 |
vitro studies | 20 |
acute hepatic | 20 |
minute ventilation | 20 |
lower tidal | 20 |
healthy controls | 20 |
ii pneumocytes | 20 |
assisted ventilation | 20 |
closely related | 20 |
aplastic anemia | 20 |
para evitar | 20 |
selected patients | 20 |
old female | 20 |
higher levels | 20 |
single lung | 20 |
test results | 20 |
surfactant protein | 20 |
aortic arch | 20 |
initial treatment | 20 |
es importante | 20 |
vooral bij | 20 |
often associated | 20 |
clinical examination | 20 |
revised atlanta | 20 |
cochrane review | 20 |
afhankelijk van | 20 |
year mortality | 20 |
respiratory insufficiency | 20 |
cardiovascular complications | 20 |
routine use | 20 |
human metapneumovirus | 20 |
well tolerated | 20 |
neurological complications | 20 |
antiviral therapy | 20 |
significant changes | 20 |
venous blood | 20 |
natriuretic peptide | 20 |
autopsy findings | 20 |
chronic pulmonary | 20 |
clinical data | 20 |
trimethoprim sulfamethoxazole | 20 |
es el | 20 |
zie ook | 20 |
phase ii | 20 |
mixed venous | 20 |
infectious mononucleosis | 20 |
may require | 20 |
patients showed | 20 |
en china | 20 |
cardiac injury | 20 |
seasonal influenza | 20 |
watery diarrhea | 20 |
persistent infection | 20 |
amino acid | 20 |
polyarteritis nodosa | 20 |
pseudomonas aeruginosa | 20 |
failure caused | 20 |
ards may | 20 |
serum levels | 20 |
innate immune | 20 |
tratamiento con | 20 |
coronary syndrome | 20 |
treatment group | 20 |
estos pacientes | 20 |
pathologic findings | 20 |
cellular rejection | 20 |
least days | 20 |
delle emad | 20 |
surgical icu | 20 |
phase iii | 20 |
studies suggest | 20 |
three different | 20 |
lavage fluid | 20 |
risk patients | 19 |
serologic studies | 19 |
patients suffering | 19 |
will also | 19 |
alto flujo | 19 |
acute pharyngo | 19 |
multiorgan failure | 19 |
median age | 19 |
host immune | 19 |
significant correlation | 19 |
coagulation factors | 19 |
placebo group | 19 |
cord blood | 19 |
cual se | 19 |
confirmed cases | 19 |
negative predictive | 19 |
per minute | 19 |
many cases | 19 |
support ventilation | 19 |
mucous membranes | 19 |
inflammatory reaction | 19 |
clinical presentations | 19 |
protease inhibitors | 19 |
sputum purulence | 19 |
mean duration | 19 |
one hour | 19 |
scarlet fever | 19 |
rapidly progressive | 19 |
independently associated | 19 |
standard deviation | 19 |
breathing pattern | 19 |
inflammatory markers | 19 |
epithelial cell | 19 |
decreased significantly | 19 |
probable sars | 19 |
positive airway | 19 |
avascular necrosis | 19 |
annular erythema | 19 |
lung ultrasound | 19 |
potential therapeutic | 19 |
white cell | 19 |
adverse outcome | 19 |
los cuales | 19 |
entre los | 19 |
respiratory mechanics | 19 |
airway inflammation | 19 |
fibrin deposition | 19 |
severe sars | 19 |
chronic lung | 19 |
statistical significance | 19 |
univariate analysis | 19 |
successful treatment | 19 |
glasgow coma | 19 |
analysis showed | 19 |
cirrhotic patients | 19 |
mg twice | 19 |
old male | 19 |
may include | 19 |
hasta el | 19 |
native lung | 19 |
high flow | 19 |
southern china | 19 |
adipose tissue | 19 |
clinical evidence | 19 |
different types | 19 |
lo tanto | 19 |
poor outcomes | 19 |
neurologic complications | 19 |
cough illness | 18 |
severe coronavirus | 18 |
comorbid conditions | 18 |
shock patients | 18 |
signaling pathway | 18 |
status epilepticus | 18 |
syndrome acute | 18 |
symptoms may | 18 |
maxillary sinusitis | 18 |
prospectively studied | 18 |
gram stain | 18 |
erythropoietic protoporphyria | 18 |
nine patients | 18 |
jugular vein | 18 |
controlled clinical | 18 |
infectious complications | 18 |
tratados con | 18 |
causative agent | 18 |
medical intensive | 18 |
improved survival | 18 |
autoimmune hepatitis | 18 |
last years | 18 |
las recomendaciones | 18 |
patient died | 18 |
renal transplant | 18 |
en zijde | 18 |
acute hypoxemic | 18 |
small number | 18 |
study found | 18 |
leg ulcers | 18 |
wide variety | 18 |
nutritional support | 18 |
low risk | 18 |
ventricular failure | 18 |
lung water | 18 |
alveolar macrophages | 18 |
arterial oxygen | 18 |
obstructive lung | 18 |
studies show | 18 |
cardiac failure | 18 |
four patients | 18 |
se sugiere | 18 |
may provide | 18 |
forma rutinaria | 18 |
neutrophil elastase | 18 |
viral respiratory | 18 |
onderdeel van | 18 |
opportunistic infections | 18 |
exogenous surfactant | 18 |
troponin i | 18 |
lung involvement | 18 |
recomienda en | 18 |
patients develop | 18 |
acute febrile | 18 |
hsct patients | 18 |
surgical lung | 18 |
toxic effects | 18 |
acuerdo con | 18 |
high level | 18 |
clinical evaluation | 18 |
increased sputum | 18 |
coronary angiography | 18 |
three groups | 18 |
acute heart | 18 |
high morbidity | 18 |
con enfermedad | 18 |
internal medicine | 18 |
cuando se | 18 |
glomerular filtration | 18 |
ischemic heart | 18 |
reduce mortality | 18 |
antibody response | 18 |
het slijmvlies | 18 |
diagnostic tests | 18 |
deep vein | 18 |
los efectos | 18 |
high concentrations | 18 |
body mass | 18 |
extracorporeal life | 18 |
acute cellular | 18 |
pulmonary infections | 18 |
neurological symptoms | 18 |
fat embolism | 18 |
may reduce | 18 |
cardiopulmonary bypass | 18 |
clinical failure | 18 |
cell injury | 18 |
complement activation | 18 |
several weeks | 18 |
early detection | 18 |
ventricular tachycardia | 18 |
microbiologic study | 18 |
oxygen species | 18 |
experimental studies | 18 |
nuclear factor | 18 |
mean sd | 17 |
injury acute | 17 |
murine model | 17 |
cor pulmonale | 17 |
pericardial effusion | 17 |
lo cual | 17 |
control measures | 17 |
mrna decay | 17 |
six patients | 17 |
natural products | 17 |
decision making | 17 |
findings include | 17 |
first time | 17 |
underlying lung | 17 |
lumbar puncture | 17 |
must also | 17 |
scoring systems | 17 |
el estudio | 17 |
del covid | 17 |
giant cells | 17 |
pancreatic necrosis | 17 |
severe complications | 17 |
una estrategia | 17 |
personal protective | 17 |
uitval van | 17 |
systolic blood | 17 |
filtration rate | 17 |
pain relief | 17 |
tissue disease | 17 |
cell culture | 17 |
antitrypsin deficiency | 17 |
vascular permeability | 17 |
systemic vascular | 17 |
may increase | 17 |
parainfluenza virus | 17 |
study included | 17 |
en covid | 17 |
volume ventilation | 17 |
prospective cohort | 17 |
sulfuryl fluoride | 17 |
stress disorder | 17 |
infective endocarditis | 17 |
antimicrobial treatment | 17 |
contar con | 17 |
hemodynamic instability | 17 |
prosthetic repair | 17 |
confluent necrosis | 17 |
sedimentation rate | 17 |
medical treatment | 17 |
gas pharyngitis | 17 |
clinical severity | 17 |
tracheal intubation | 17 |
clinical use | 17 |
ethics committee | 17 |
cell necrosis | 17 |
antiviral treatment | 17 |
adverse reactions | 17 |
failure acute | 17 |
histologic sections | 17 |
shiga toxin | 17 |
cerebral oedema | 17 |
definitive diagnosis | 17 |
recent advances | 17 |
coronavirus replication | 17 |
het oor | 17 |
kidney failure | 17 |
inflammatory cytokine | 17 |
acute rhinosinusitis | 17 |
symptom onset | 17 |
patients usually | 17 |
reverse transcription | 17 |
wedge pressure | 17 |
hours later | 17 |
cerebral blood | 17 |
high prevalence | 17 |
liver tissue | 17 |
hospital admission | 17 |
term outcomes | 17 |
cardiac disease | 17 |
patients studied | 17 |
acute encephalopathy | 17 |
i min | 17 |
atypical pneumonia | 17 |
bij kinderen | 17 |
tested positive | 17 |
monoclonal antibody | 17 |
nosocomial pneumonia | 17 |
lymphocytic myocarditis | 17 |
steroid therapy | 17 |
within minutes | 17 |
cols en | 16 |
results patients | 16 |
injury caused | 16 |
one lung | 16 |
sars cases | 16 |
en estado | 16 |
inflammatory cell | 16 |
paranasal sinuses | 16 |
elevation myocardial | 16 |
fluid responsiveness | 16 |
etiologic agents | 16 |
pleural effusions | 16 |
two different | 16 |
laboratory studies | 16 |
cell transplant | 16 |
helicobacter pylori | 16 |
healthy volunteers | 16 |
airflow obstruction | 16 |
healthy subjects | 16 |
pathological changes | 16 |
los trabajadores | 16 |
standard care | 16 |
every hours | 16 |
chronic hbv | 16 |
year follow | 16 |
old man | 16 |
three times | 16 |
partial pressure | 16 |
desde el | 16 |
blood coagulation | 16 |
mental status | 16 |
fulminant liver | 16 |
possible causes | 16 |
tympanic membrane | 16 |
chest wall | 16 |
diagnostic test | 16 |
infections may | 16 |
protective equipment | 16 |
independent factors | 16 |
bacterial colonization | 16 |
antibiotic prescribing | 16 |
single center | 16 |
sars virus | 16 |
comparado con | 16 |
stromal cells | 16 |
bacterial peritonitis | 16 |
ill patient | 16 |
organ donation | 16 |
relatively high | 16 |
durante el | 16 |
emerging infectious | 16 |
hemorrhagic fever | 16 |
bacterial rhinosinusitis | 16 |
ct pulmonary | 16 |
stage renal | 16 |
common respiratory | 16 |
sars outbreak | 16 |
low tidal | 16 |
combination therapy | 16 |
regression analyses | 16 |
neuromuscular blockade | 16 |
las condiciones | 16 |
record weight | 16 |
viral gastroenteritis | 16 |
frequently used | 16 |
del tratamiento | 16 |
mononuclear cell | 16 |
clinical prediction | 16 |
smoking cessation | 16 |
disease patients | 16 |
patients developed | 16 |
international consensus | 16 |
transbronchial lung | 16 |
throat cultures | 16 |
usually present | 16 |
una vez | 16 |
serum samples | 16 |
data analysis | 16 |
severe infection | 16 |
acute poisoning | 16 |
tertiary care | 16 |
currently available | 16 |
infection acute | 16 |
acute tubular | 16 |
han sido | 16 |
manejo del | 16 |
acute streptococcal | 16 |
early acute | 16 |
mg day | 16 |
cell lines | 16 |
severity score | 16 |
compromiso pulmonar | 16 |
human infection | 16 |
spontaneous bacterial | 16 |
significant proportion | 16 |
increased incidence | 16 |
acute stroke | 16 |
positive blood | 16 |
internal jugular | 16 |
prepare roentgenograms | 16 |
painful episodes | 16 |
severe hypoxemia | 16 |
commonly seen | 16 |
monoclonal antibodies | 16 |
seven patients | 16 |
transforming growth | 16 |
acute sars | 16 |
carga viral | 16 |
hemorrhagic edema | 16 |
without evidence | 16 |
progenitor cells | 16 |
year survival | 16 |
plasma exchange | 16 |
heart association | 16 |
blood glucose | 16 |
clinical decision | 16 |
patients aged | 16 |
imaging studies | 16 |
activated charcoal | 16 |
oral cavity | 16 |
specific antibodies | 16 |
venous thrombosis | 16 |
erythema annulare | 15 |
meld score | 15 |
sickle rbc | 15 |
case fatality | 15 |
energy ct | 15 |
tract disease | 15 |
metabolic acidosis | 15 |
body fluids | 15 |
urine output | 15 |
recomienda realizar | 15 |
las cuales | 15 |
los niveles | 15 |
type unspecified | 15 |
autosomal dominant | 15 |
coma scale | 15 |
tissue plasminogen | 15 |
air bronchogram | 15 |
proven myocarditis | 15 |
animal model | 15 |
mediated mrna | 15 |
affected individuals | 15 |
respiratory muscles | 15 |
prospective observational | 15 |
stage liver | 15 |
los recursos | 15 |
sputum volume | 15 |
invasive aspergillosis | 15 |
dificultad respiratoria | 15 |
massive pulmonary | 15 |
care setting | 15 |
comparative study | 15 |
annulare centrifugum | 15 |
direct viral | 15 |
significant improvement | 15 |
study clinical | 15 |
inducible nitric | 15 |
stable copd | 15 |
old woman | 15 |
los servicios | 15 |
healthy adults | 15 |
artery disease | 15 |
center study | 15 |
cerebral perfusion | 15 |
alveolar space | 15 |
early treatment | 15 |
free radicals | 15 |
also common | 15 |
open heart | 15 |
autopsy procedures | 15 |
lymphocytic bronchiolitis | 15 |
liver regeneration | 15 |
important cause | 15 |
cell surface | 15 |
one hundred | 15 |
bowel disease | 15 |
mortality among | 15 |
treating acute | 15 |
respiratory viral | 15 |
otherwise healthy | 15 |
pacientes covid | 15 |
zu einer | 15 |
las personas | 15 |
endothelial growth | 15 |
pcr assays | 15 |
fluid balance | 15 |
persistent cough | 15 |
idiopathic interstitial | 15 |
kidney transplant | 15 |
spike glycoprotein | 15 |
molecular biology | 15 |
medical staff | 15 |
developing countries | 15 |
smooth muscle | 15 |
arterial hypertension | 15 |
two studies | 15 |
pueden ser | 15 |
acute physiology | 15 |
will help | 15 |
favor fundamento | 15 |
frozen plasma | 15 |
commonly associated | 15 |
supine position | 15 |
mass index | 15 |
usually associated | 15 |
american heart | 15 |
host cell | 15 |
higher rate | 15 |
expiratory flow | 15 |
emitir una | 15 |
histologic examination | 15 |
care med | 15 |
para su | 15 |
zwelling van | 15 |
el estado | 15 |
reperfusion injury | 15 |
pacientes hospitalizados | 15 |
angiotensin converting | 15 |
china clinical | 15 |
platelet activation | 15 |
si se | 15 |
cell proliferation | 15 |
microbiologic response | 15 |
inflammatory process | 15 |
adrenal insufficiency | 15 |
effective treatment | 15 |
clinical manifestation | 15 |
organ systems | 15 |
disease caused | 15 |
first year | 15 |
effi cacy | 15 |
cell types | 15 |
fatality rate | 15 |
coagulation dysfunction | 15 |
sweet syndrome | 15 |
failure secondary | 15 |
corona virus | 15 |
neurological diseases | 15 |
rescue therapy | 15 |
thrombotic microangiopathy | 15 |
pulmonary capillary | 15 |
interstitial nephritis | 15 |
prolonged mechanical | 15 |
negative pressure | 15 |
based study | 15 |
incidence rate | 15 |
pandemic influenza | 15 |
severe form | 15 |
mild cases | 15 |
national health | 15 |
standard therapy | 15 |
homozygous protein | 15 |
systemic corticosteroids | 15 |
descriptive study | 15 |
moraxella catarrhalis | 15 |
care providers | 15 |
acute maxillary | 15 |
acute gvhd | 15 |
whenever possible | 15 |
perivascular mononuclear | 15 |
clinical efficacy | 15 |
cardiac troponin | 14 |
clinical syndrome | 14 |
well known | 14 |
gastroesophageal reflux | 14 |
en paciente | 14 |
cells may | 14 |
rapid diagnosis | 14 |
hbv replication | 14 |
therapeutic strategies | 14 |
may suggest | 14 |
como una | 14 |
important roles | 14 |
regression analysis | 14 |
like protease | 14 |
month period | 14 |
several months | 14 |
decreased mortality | 14 |
receive either | 14 |
entre el | 14 |
epub ahead | 14 |
primary infection | 14 |
part ii | 14 |
chest physiotherapy | 14 |
blind study | 14 |
neutralizing antibody | 14 |
approximately one | 14 |
ha sido | 14 |
hepatocyte transplantation | 14 |
older children | 14 |
combinatie met | 14 |
artery bypass | 14 |
individual patients | 14 |
health problem | 14 |
renal aguda | 14 |
inflammatory bowel | 14 |
extracellular traps | 14 |
transbronchial biopsies | 14 |
thrombotic thrombocytopenic | 14 |
study conducted | 14 |
clavulanic acid | 14 |
fungal infection | 14 |
european consensus | 14 |
intubated patients | 14 |
term mortality | 14 |
overall survival | 14 |
lymphoproliferative disorders | 14 |
blood count | 14 |
extravascular lung | 14 |
del personal | 14 |
dose corticosteroids | 14 |
bacterial pathogen | 14 |
low molecular | 14 |
natural killer | 14 |
lung damage | 14 |
two zones | 14 |
severely ill | 14 |
remains unknown | 14 |
weight heparin | 14 |
bacterial sinusitis | 14 |
initial chest | 14 |
donde se | 14 |
animal studies | 14 |
remains controversial | 14 |
als auch | 14 |
bronchogram sign | 14 |
following lung | 14 |
whole blood | 14 |
neonatal purpura | 14 |
host cells | 14 |
pneumocystis carinii | 14 |
para evaluar | 14 |
following parameters | 14 |
hemodynamically stable | 14 |
respiratory disorders | 14 |
en bij | 14 |
nosocomial infection | 14 |
urea nitrogen | 14 |
immune deficiency | 14 |
del uso | 14 |
heart transplant | 14 |
macrophage activation | 14 |
organ damage | 14 |
type patients | 14 |
deben ser | 14 |
intravenous infusion | 14 |
host factors | 14 |
pandemia covid | 14 |
otitis externa | 14 |
required mechanical | 14 |
large numbers | 14 |
cell infiltration | 14 |
neonatal period | 14 |
kupffer cells | 14 |
hepatitis virus | 14 |
nasopharyngeal swab | 14 |
therapeutic intervention | 14 |
copd exacerbation | 14 |
int csr | 14 |
inferior vena | 14 |
intercellular adhesion | 14 |
clinical setting | 14 |
con pacientes | 14 |
neutrophil extracellular | 14 |
sistema nervoso | 14 |
american academy | 14 |
palliative care | 14 |
systolic function | 14 |
positive predictive | 14 |
inspired oxygen | 14 |
surgical intervention | 14 |
pediatric intensive | 14 |
heart strain | 14 |
clinically significant | 14 |
vascular rejection | 14 |
three days | 14 |
recombinant human | 14 |
medical icu | 14 |
also cause | 14 |
first case | 14 |
el traslado | 14 |
protease inhibitor | 14 |
secondary infection | 14 |
drug administration | 14 |
dna vaccine | 14 |
thrombolytic therapy | 14 |
es necesario | 14 |
viral shedding | 14 |
healthy patients | 14 |
clinical parameters | 14 |
treat acute | 14 |
pulmonary toxicity | 14 |
ganz catheter | 14 |
mortality benefit | 14 |
myocarditis associated | 14 |
healthy adult | 14 |
children younger | 14 |
died within | 14 |
el sars | 14 |
less commonly | 14 |
health status | 14 |
cutaneous manifestations | 14 |
chronic cough | 14 |
control groups | 14 |
birth weight | 14 |
confidence interval | 14 |
may become | 14 |
asociado con | 14 |
blood culture | 14 |
last decade | 14 |
nonstructural protein | 13 |
hepatic dysfunction | 13 |
partial thromboplastin | 13 |
open lung | 13 |
tubulointerstitial nephritis | 13 |
positive results | 13 |
un mayor | 13 |
csr sars | 13 |
el objetivo | 13 |
nursing staff | 13 |
generation cephalosporins | 13 |
conscious rats | 13 |
infected cells | 13 |
associated encephalopathy | 13 |
epidemiologic studies | 13 |
sinus maxillaris | 13 |
normal subjects | 13 |
extracellular matrix | 13 |
weight loss | 13 |
healthcare workers | 13 |
adult lung | 13 |
falla renal | 13 |
cell therapy | 13 |
pulmonary gas | 13 |
interim guidance | 13 |
serious complications | 13 |
thromboembolic disease | 13 |
cell carcinoma | 13 |
mesenchymal stromal | 13 |
study acute | 13 |
fresh frozen | 13 |
fluid clearance | 13 |
bacterial meningitis | 13 |
test probability | 13 |
human mesenchymal | 13 |
ascending aorta | 13 |
severe pulmonary | 13 |
changes may | 13 |
therapeutic options | 13 |
may indicate | 13 |
soft tissue | 13 |
alveolar spaces | 13 |
albumin dialysis | 13 |
vascular endothelium | 13 |
increased susceptibility | 13 |
roc curve | 13 |
may need | 13 |
lung compliance | 13 |
con hipoxemia | 13 |
complete heart | 13 |
line therapy | 13 |
forced expiratory | 13 |
della sostanza | 13 |
vertical transmission | 13 |
volume expansion | 13 |
ten patients | 13 |
inflammatory drugs | 13 |
factor vii | 13 |
encephalitis encephalopathy | 13 |
chronic vascular | 13 |
patient groups | 13 |
cardiac transplantation | 13 |
small intestine | 13 |
constant flow | 13 |
mean value | 13 |
complete recovery | 13 |
alanine aminotransferase | 13 |
alto riesgo | 13 |
aortic valve | 13 |
total bilirubin | 13 |
en cuanto | 13 |
findings may | 13 |
erythema gyratum | 13 |
least two | 13 |
underlying conditions | 13 |
atrial septal | 13 |
inflammatory responses | 13 |
study design | 13 |
alveolar fluid | 13 |
bordetella pertussis | 13 |
group iii | 13 |
con respecto | 13 |
bei patienten | 13 |
oxygen extraction | 13 |
surgical treatment | 13 |
randomized study | 13 |
carrier state | 13 |
suppurative complications | 13 |
much lower | 13 |
flow cytometry | 13 |
drug overdose | 13 |
ventilator associated | 13 |
myocardial ischemia | 13 |
liver fibrosis | 13 |
met een | 13 |
van gieson | 13 |
acute severe | 13 |
supportive treatment | 13 |
sputum culture | 13 |
stroke volume | 13 |
patient presented | 13 |
new coronavirus | 13 |
virus replication | 13 |
erythrocyte sedimentation | 13 |
hepatic coma | 13 |
systemic sclerosis | 13 |
see disease | 13 |
core promoter | 13 |
continuous positive | 13 |
acute encephalitis | 13 |
pg kg | 13 |
cytokine release | 13 |
clinical cure | 13 |
close contact | 13 |
may improve | 13 |
gene promoter | 13 |
inspiratory pressure | 13 |
samples collected | 13 |
disease following | 13 |
two types | 13 |
vascular diseases | 13 |
severe exacerbations | 13 |
multivariable logistic | 13 |
ipratropium bromide | 13 |
allograft biopsies | 13 |
clinical conditions | 13 |
femoral artery | 13 |
gestational age | 13 |
alveolar septa | 13 |
authors declare | 13 |
virus type | 13 |
american society | 13 |
con las | 13 |
three major | 13 |
national institutes | 13 |
studies using | 13 |
saudi arabia | 13 |
ambulatory care | 13 |
american association | 13 |
av block | 13 |
two hours | 13 |
spectrum antibiotics | 13 |
remained unchanged | 13 |
respiratory muscle | 13 |
sepsis syndrome | 13 |
liver enzymes | 13 |
multiple trauma | 13 |
hospitalizados con | 13 |
renal transplantation | 13 |
un protocolo | 13 |
necrotizing pancreatitis | 13 |
el consentimiento | 13 |
often used | 13 |
los criterios | 13 |
tracheal pressure | 13 |
activator inhibitor | 13 |
early use | 13 |
thrombocytopenic purpura | 13 |
opioid analgesics | 13 |
methenamine silver | 13 |
disminuir el | 13 |
phase trial | 13 |
esophageal pressure | 13 |
phase i | 13 |
recent evidence | 13 |
estancia en | 13 |
term follow | 13 |
patient may | 13 |
working formulation | 13 |
circulatory failure | 13 |
para sars | 13 |
capillary leak | 13 |
streptococcal toxic | 13 |
radiographic findings | 13 |
als bij | 13 |
also used | 13 |
basic anomaly | 13 |
future studies | 13 |
fluid management | 13 |
basado en | 13 |
flow oxygen | 13 |
young people | 13 |
oscillatory ventilation | 13 |
chronic disease | 13 |
histopathologic features | 13 |
drug resistance | 13 |
also associated | 13 |
active myocarditis | 13 |
significant reduction | 13 |
laboratory diagnosis | 13 |
qs qt | 13 |
usually occurs | 13 |
adult inpatients | 13 |
aortic dissection | 13 |
critical patients | 13 |
deleterious effects | 13 |
lyme disease | 13 |
may persist | 13 |
genome sequence | 13 |
le lesioni | 13 |
infectious bronchitis | 13 |
fatal outcome | 13 |
potential role | 13 |
donor blood | 13 |
tissue oxygenation | 13 |
defi nition | 13 |
treatment strategies | 13 |
amoxicillin clavulanate | 13 |
first described | 13 |
severe pneumonia | 13 |
control subjects | 13 |
chest ct | 13 |
complement system | 13 |
possible role | 13 |
bij het | 13 |
amoxicillin clavulanic | 13 |
traditional tidal | 13 |
complications associated | 12 |
murine myocarditis | 12 |
continuous infusion | 12 |
idiopathic dilated | 12 |
interstitial pneumonitis | 12 |
pacientes recibieron | 12 |
aspiration pneumonia | 12 |
microbiologic diagnosis | 12 |
studies showed | 12 |
drug reactions | 12 |
antibacterial therapy | 12 |
nsp nsp | 12 |
toxin production | 12 |
frecuencia respiratoria | 12 |
plasma lactate | 12 |
clostridium difficile | 12 |
increasingly recognized | 12 |
drug therapy | 12 |
constrained nations | 12 |
bloody diarrhea | 12 |
study reported | 12 |
antiviral agents | 12 |
nervoso centrale | 12 |
en het | 12 |
acute ischemic | 12 |
alcohol concentration | 12 |
injury score | 12 |
angiotensin ii | 12 |
bepaling van | 12 |
cell pain | 12 |
respiratory illnesses | 12 |
hepatopulmonary syndrome | 12 |
mayor riesgo | 12 |
study shows | 12 |
post hoc | 12 |
successfully treated | 12 |
ventilator settings | 12 |
histopathologic findings | 12 |
flow rates | 12 |
pain management | 12 |
tener en | 12 |
pressure sores | 12 |
usually presents | 12 |
therapeutic efficacy | 12 |
five cases | 12 |
weaning protocol | 12 |
right atrium | 12 |
patients compared | 12 |
niv failure | 12 |
proliferative gn | 12 |
vaak ook | 12 |
therapeutic effect | 12 |
vrijwel altijd | 12 |
dry cough | 12 |
dissection techniques | 12 |
grupo control | 12 |
morphologic features | 12 |
vascular disease | 12 |
developed acute | 12 |
skin biopsy | 12 |
hematologic malignancies | 12 |
skeletal muscle | 12 |
organ system | 12 |
frequently associated | 12 |
predict outcome | 12 |
transmission dynamics | 12 |
table i | 12 |
ace inhibitors | 12 |
acute brain | 12 |
fulminant myocarditis | 12 |
barre syndrome | 12 |
growth factors | 12 |
also important | 12 |
las muestras | 12 |
clinical specimens | 12 |
also showed | 12 |
mg ml | 12 |
relevant outcomes | 12 |
bile ducts | 12 |
ductal artery | 12 |
nasal congestion | 12 |
ct scans | 12 |
every patient | 12 |
angiotensin system | 12 |
pulmonary involvement | 12 |
cuenta con | 12 |
volume replacement | 12 |
med doi | 12 |
com scientificreports | 12 |
cases may | 12 |
porphyria cutanea | 12 |
basal ganglia | 12 |
rights reserved | 12 |
red cells | 12 |
peritoneal dialysis | 12 |
nasal cavity | 12 |
respiratory acidosis | 12 |
proposed template | 12 |
studies demonstrated | 12 |
influenza viruses | 12 |
food poisoning | 12 |
resistant bacteria | 12 |
driving pressure | 12 |
tested negative | 12 |
el rendimiento | 12 |
often present | 12 |
two days | 12 |
histologic findings | 12 |
invloed van | 12 |
diagnostic accuracy | 12 |
neutralizing antibodies | 12 |
los resultados | 12 |
uso del | 12 |
drug toxicity | 12 |
european study | 12 |
preliminary results | 12 |
fatty changes | 12 |
viral etiology | 12 |
high rates | 12 |
significantly decreased | 12 |
aged years | 12 |
hydrops fetalis | 12 |
allograft dysfunction | 12 |
also play | 12 |
hemodynamic effects | 12 |
key role | 12 |
study using | 12 |
hypersensitivity myocarditis | 12 |
vast majority | 12 |
tyrosine kinase | 12 |
el contexto | 12 |
coagulation parameters | 12 |
disease acute | 12 |
diagnostic tools | 12 |
might also | 12 |
acuta disseminata | 12 |
greater risk | 12 |
orthotopic liver | 12 |
protective effects | 12 |
case definition | 12 |
relatively low | 12 |
receiver operating | 12 |
annual report | 12 |
among covid | 12 |
hemorrhagic leukoencephalitis | 12 |
direct examination | 12 |
therapeutic effects | 12 |
etiologic agent | 12 |
human lung | 12 |
infi ltrate | 12 |
cause acute | 12 |
patients present | 12 |
por coronavirus | 12 |
may represent | 12 |
pulmonary inflammation | 12 |
chronic severe | 12 |
silver stain | 12 |
pleural fluid | 12 |
may explain | 12 |
bioartificial liver | 12 |
patients presented | 12 |
mouse model | 12 |
community acquired | 12 |
kawasaki syndrome | 12 |
host response | 12 |
fluid collections | 12 |
viral loads | 12 |
medical records | 12 |
protective ventilation | 12 |
clinical benefit | 12 |
bioactive compounds | 12 |
room air | 12 |
intrahepatic cholestasis | 12 |
clinical investigations | 12 |
united kingdom | 12 |
myocyte necrosis | 12 |
many studies | 12 |
prospective studies | 12 |
imaging findings | 12 |
nasopharyngeal aspirates | 12 |
chiari malformation | 12 |
thrombotic complications | 12 |
clinical scores | 12 |
en salud | 12 |
blind trial | 12 |
arterial ph | 12 |
autopsy cases | 12 |
human leukocyte | 12 |
ziek zijn | 12 |
systemic sepsis | 12 |
interaction partners | 12 |
control drug | 12 |
las medidas | 12 |
every day | 12 |
treatment protocol | 12 |
surviving sepsis | 12 |
conventional therapy | 12 |
onset vap | 12 |
cutanea tarda | 12 |
flail chest | 12 |
als onderdeel | 12 |
acute tonsillitis | 12 |
pediatric neurosurgery | 12 |
fluid overload | 12 |
las primeras | 12 |
surfactant therapy | 12 |
pulmonary pathology | 12 |
igg antibodies | 12 |
common clinical | 12 |
recent meta | 12 |
severe forms | 12 |
recruitment maneuvers | 12 |
hemodynamic monitoring | 12 |
puede emitir | 12 |
chronic respiratory | 12 |
brain damage | 12 |
serum albumin | 12 |
new onset | 12 |
probably due | 12 |
los primeros | 12 |
left heart | 12 |
typhoid fever | 12 |
alcoholic liver | 12 |
average age | 12 |
presumed microbiologic | 12 |
significant mortality | 11 |
del equipo | 11 |
sars epidemic | 11 |
main causes | 11 |
protective role | 11 |
estudio retrospectivo | 11 |
per se | 11 |
renal insufficiency | 11 |
low doses | 11 |
treatment regimens | 11 |
possible cause | 11 |
cardiac myocytes | 11 |
hypersensitivity pneumonitis | 11 |
promoter region | 11 |
continuous monitoring | 11 |
highly pathogenic | 11 |
pregnant patients | 11 |
injury induced | 11 |
recomienda el | 11 |
prospective trial | 11 |
chronic graft | 11 |
times daily | 11 |
sepsis campaign | 11 |
brain natriuretic | 11 |
resistant strains | 11 |
clinical condition | 11 |
per patient | 11 |
sars infection | 11 |
single dose | 11 |
algemeen ziek | 11 |
short period | 11 |
acute painful | 11 |
within normal | 11 |
congenital syphilis | 11 |
mpm ii | 11 |
frequently observed | 11 |
immunosuppressive agents | 11 |
widespread use | 11 |
conduction system | 11 |
four cases | 11 |
correct diagnosis | 11 |
record extent | 11 |
preliminary study | 11 |
nk cells | 11 |
related quality | 11 |
immune function | 11 |
evidence supporting | 11 |
syndrome pulmonary | 11 |
renal biopsy | 11 |
femoral vein | 11 |
different levels | 11 |
ballooning degeneration | 11 |
manuscript www | 11 |
respiratory function | 11 |
el fin | 11 |
bronchial secretions | 11 |
intravenous administration | 11 |
without antibiotics | 11 |
physical exam | 11 |
circulating antibodies | 11 |
functional status | 11 |
expiratory volume | 11 |
oxygen transport | 11 |
los siguientes | 11 |
hepatocyte necrosis | 11 |
antimicrobial agent | 11 |
several days | 11 |
posttraumatic stress | 11 |
endothelial dysfunction | 11 |
ventricular ejection | 11 |
viral encephalitis | 11 |
clinical cases | 11 |
renal injury | 11 |
phrenic nerve | 11 |
high probability | 11 |
sporadic cases | 11 |
different stages | 11 |
commercially available | 11 |
time interval | 11 |
por un | 11 |
steroid treatment | 11 |
ground glass | 11 |
pulmonary valve | 11 |
general dissection | 11 |
cardiac sarcoidosis | 11 |
intestinal tract | 11 |
different clinical | 11 |
laboratory data | 11 |
lactic acid | 11 |
dose loracarbef | 11 |
sostanza bianca | 11 |
improved outcomes | 11 |
therapeutic management | 11 |
antibiotics may | 11 |
older patients | 11 |
medical therapy | 11 |
rna polymerase | 11 |
oral rehydration | 11 |
urinary bladder | 11 |
appropriate therapy | 11 |
pediatric acute | 11 |
activating factor | 11 |
symptoms include | 11 |
neuraminidase inhibitors | 11 |
este estudio | 11 |
nonsteroidal anti | 11 |
unfractionated heparin | 11 |
varying degrees | 11 |
may still | 11 |
ascorbic acid | 11 |
chiari i | 11 |
metabolic disorders | 11 |
focal segmental | 11 |
surgery patients | 11 |
blood agar | 11 |
nonspecific interstitial | 11 |
coronavirus rna | 11 |
gi bleeding | 11 |
cell entry | 11 |
reduced mortality | 11 |
acute lower | 11 |
vascular tone | 11 |
will increase | 11 |
reportable disease | 11 |
management strategies | 11 |
randomized double | 11 |
el nivel | 11 |
mass spectrometry | 11 |
anticoagulant therapy | 11 |
studies reported | 11 |
training period | 11 |
similar results | 11 |
media met | 11 |
autoimmune disease | 11 |
los medicamentos | 11 |
gene therapy | 11 |
palatum molle | 11 |
observational cohort | 11 |
perfusion pressure | 11 |
require mechanical | 11 |
nipah virus | 11 |
heart muscle | 11 |
toxicological analysis | 11 |
un paciente | 11 |
prospective multicenter | 11 |
frozen sections | 11 |
infectious process | 11 |
serologic evidence | 11 |
sodium chlorate | 11 |
viral pneumonia | 11 |
early recognition | 11 |
clinical success | 11 |
showed significant | 11 |
airway resistance | 11 |
inflammatory infiltrate | 11 |
treatment options | 11 |
least hours | 11 |
community outbreak | 11 |
developed countries | 11 |
reporting template | 11 |
platelet counts | 11 |
volume overload | 11 |
toxicologic sampling | 11 |
ecg abnormalities | 11 |
moderately severe | 11 |
bronchial hyperresponsiveness | 11 |
enfermedad severa | 11 |
protein levels | 11 |
frequency oscillatory | 11 |
brachial plexus | 11 |
cuidados paliativos | 11 |
including patients | 11 |
fibrosis may | 11 |
extracorporeal liver | 11 |
suspected underlying | 11 |
como los | 11 |
throat swab | 11 |
respiratorio agudo | 11 |
inflammatory infiltrates | 11 |
may produce | 11 |
may involve | 11 |
identify factors | 11 |
individual patient | 11 |
thoracic surgery | 11 |
consensus statement | 11 |
acute inflammation | 11 |
cmv infection | 11 |
oxygen supplementation | 11 |
rapid test | 11 |
clinically relevant | 11 |
clinical research | 11 |
patients diagnosed | 11 |
agent orange | 11 |
study population | 11 |
within months | 11 |
rna virus | 11 |
secundair aan | 11 |
severe illness | 11 |
years ago | 11 |
significantly greater | 11 |
significant benefit | 11 |
data obtained | 11 |
data collection | 11 |
may reflect | 11 |
pacientes tratados | 11 |
drug reaction | 11 |
complete resolution | 11 |
cell cultures | 11 |
independent predictors | 11 |
prepare photographs | 11 |
standard treatment | 11 |
ml vs | 11 |
existe una | 11 |
systemic infection | 11 |
improves survival | 11 |
unpublished data | 11 |
mean pulmonary | 11 |
febrile illness | 11 |
frequency jet | 11 |
con mayor | 11 |
una sclerosi | 11 |
invasive positive | 11 |
negative results | 11 |
grade fever | 11 |
efectos adversos | 11 |
proinflammatory mediators | 11 |
patients whose | 11 |
groups according | 11 |
genetic factors | 11 |
total number | 11 |
primary cause | 11 |
ha demostrado | 11 |
lesions may | 11 |
outcome measure | 11 |
time pcr | 11 |
viral entry | 11 |
allogeneic hematopoietic | 11 |
clinical scoring | 11 |
improve outcome | 11 |
crit care | 11 |
less severe | 11 |
large amounts | 11 |
biliary tract | 11 |
peep levels | 11 |
risk stratification | 11 |
transthoracic echocardiography | 11 |
term prognosis | 11 |
unnecessary antibiotic | 11 |
paediatric patients | 11 |
diastolic dysfunction | 11 |
aumento en | 11 |
multicenter trial | 11 |
therapeutic targets | 11 |
cases per | 11 |
lung volume | 11 |
host defense | 11 |
severe symptoms | 11 |
electron microscopic | 11 |
percutaneous coronary | 11 |
response rate | 11 |
molecular adsorbent | 11 |
syndrome clinical | 11 |
classifi cation | 11 |
significantly elevated | 11 |
inclusion criteria | 11 |
vascular occlusion | 11 |
traumatic brain | 11 |
main cause | 11 |
plateau pressure | 11 |
acute illness | 11 |
studies may | 11 |
con tcz | 11 |
interferon alfacon | 11 |
ischemia reperfusion | 11 |
hepatocyte growth | 11 |
respiratory secretions | 11 |
survival rates | 11 |
granulocyte colony | 10 |
bacterial culture | 10 |
respiratory diseases | 10 |
susceptibility testing | 10 |
aki incidence | 10 |
ventilation strategy | 10 |
arterial oxygenation | 10 |
colony stimulating | 10 |
cerebrovascular disease | 10 |
continuous renal | 10 |
causal relationship | 10 |
allogeneic bone | 10 |
risk groups | 10 |
south america | 10 |
different countries | 10 |
may even | 10 |
patients require | 10 |
icu length | 10 |
prophylactic antibiotics | 10 |
conjugate vaccine | 10 |
late phase | 10 |
stomach contents | 10 |
prospective randomized | 10 |
related liver | 10 |
first step | 10 |
unknown etiology | 10 |
encephalopathy associated | 10 |
autopsy case | 10 |
infection associated | 10 |
near future | 10 |
en tiempos | 10 |
pathologic changes | 10 |
map mmhg | 10 |
en algunos | 10 |
virus entry | 10 |
high rate | 10 |
data regarding | 10 |
blood transfusions | 10 |
coronavirus nonstructural | 10 |
eosinophilic myocarditis | 10 |
classification algorithm | 10 |
hipoxemia refractaria | 10 |
hbv quasispecies | 10 |
segmental glomerulosclerosis | 10 |
also result | 10 |
activated partial | 10 |
advanced age | 10 |
secondary infections | 10 |
significant risk | 10 |
salud mental | 10 |
organ transplant | 10 |
abnormal coagulation | 10 |
coronary syndromes | 10 |
less likely | 10 |
lung ventilation | 10 |
del plasma | 10 |
fatty acid | 10 |
clinical treatment | 10 |
door het | 10 |
inflammatory changes | 10 |
median time | 10 |
important factors | 10 |
surface antigen | 10 |
adverse outcomes | 10 |
decompressive craniectomy | 10 |
portal area | 10 |
acute episode | 10 |
blueberry muffi | 10 |